Johnson & Johnson (JNJ) Q4 2025 Earnings Call January 21, 2026 8:30 AM EST

Company Participants

Darren Snellgrove - Vice President of Investor Relations Joaquin Duato - CEO & Chairman Joseph Wolk - Executive VP & CFO Tim Schmid - Executive VP & Worldwide Chairman of MedTech Jennifer Taubert - Executive VP & Worldwide Chairman of Innovative Medicine John Reed - Executive Vice President of Innovative Medicine and R&D

Conference Call Participants

Asad Haider - Goldman Sachs Group, Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Joanne Wuensch - Citigroup Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Alexandria Hammond - Wolfe Research, LLC

Presentation

Operator

Good morning, and welcome to Johnson & Johnson’s Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded. [Operator Instructions].

I will now turn the conference call over to Johnson & Johnson. You may begin.

Darren Snellgrove Vice President of Investor Relations

Hello, everyone. This is Darren Snellgrove, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company’s review of business results for the fourth quarter and full year 2025 and our financial outlook for 2026.

First, a few logistics. As a reminder, today’s presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company’s future operating and financial performance, market position, and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording, and are subject to certain risks and uncertainties that may cause the company’s actual